Address: 8th Floor, PNB Damansara No. 19 Lorong Dungun Damansara Heights 50490 KUALA LUMPUR
Malaysia
,Malaysia
Tel: (603) 2089 3333
Web: http://www.sanofi.com.my/l/my/en/index.jsp
Sanofi-aventis Malaysia is an affiliate of the global healthcare company Sanofi-aventis. The ambition of sanofi-aventis is to become a diversified global healthcare leader, focused on patients’ needs. The largest pharmaceutical company in Europe and in emerging markets, sanofi-aventis is the fourth largest worldwide. The Group’s vaccine division, sanofi pasteur, is the world leader for human vaccine production and commercialization. With nearly 100,000 employees in over 100 countries, sanofi-aventis has core strengths in the field of healthcare: a worldwide presence, market leadership in vaccines, major biological products and a strong and long-established presence in emerging markets.
We have leading products across a range of therapeutic areas and we are committed to research and innovation to meet the current and future medical needs. Sanofi-aventis focuses its activities on 7 major therapeutic areas: Cardiovascular, Thrombosis, Oncology, Central Nervous System, Metabolic Disorders, Internal Medicine, Vaccines.
Pharmaceutical Executive is a magazine about executives, their experience and their perspectives on the pharmaceutical industry. You have worked in Australia, Hong Kong and now you are the general manager…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
